Physician profile
Mini Varghese
NPI 1548428667
$6,281.29
in general payments reported to CMS, 2019-2025
30 companies · $901 in 2025
The $901 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $647 · 2021: $1,662 · 2022: $457 · 2023: $877 · 2024: $1,207 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,848 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,848.40 |
| Education | $137.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,833.79 | 2021-2024 | Axonics |
| Coloplast Corp | $632.62 | 2019-2025 | Titan, Speedicath |
| Procept Biorobotics Corporation | $604.82 | 2022-2025 | Aquabeam System, Aquabeam Robotic System |
| Janssen Biotech, INC. | $408.67 | 2019-2025 | Rybrevant, Carvykti, Erleada |
| Rochester Medical Corporation | $370.53 | 2019-2021 | |
| Boston Scientific Corporation | $342.27 | 2019-2023 | Rezum Generator, Spaceoar Vue System - 10ml, Ams 700 |
| Myriad Genetic Laboratories, INC. | $250.13 | 2023-2025 | Prolaris, Myrisk |
| Medical Device Business Services, INC. | $217.40 | 2024 | |
| Atricure, INC. | $165.83 | 2024 | |
| Innovation Technologies INC | $157.77 | 2025 | Irrisept |
| Urogen Pharma, INC. | $141.01 | 2021 | |
| Stryker Corporation | $140.80 | 2025 | Cascadia Interbody System |
| Eagle Pharmaceuticals, INC. | $127.51 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $118.24 | 2025 | Gattex |
| Astellas Pharma US INC | $107.71 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar Pharmaceuticals, INC. | $105.49 | 2019-2022 | |
| Biotissue Holdings INC. | $80.05 | 2022 | |
| Teleflex LLC | $76.70 | 2021 | |
| Convatec INC. | $67.33 | 2019-2022 | |
| Mission Pharmacal Company | $63.15 | 2019-2021 | |
| Pfizer INC. | $41.33 | 2020 | |
| Allergan, INC. | $33.76 | 2019-2020 | |
| Olympus America INC. | $32.61 | 2021-2023 | Itind System |
| Ethicon US, LLC | $32.20 | 2019 | |
| Ferring Pharmaceuticals INC. | $26.24 | 2019 | |
| Ambu INC. | $24.50 | 2020-2024 | |
| Halozyme INC | $24.27 | 2023 | |
| Urovant Sciences INC | $20.94 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.82 | 2020 | |
| Aytu Biopharma, INC. | $14.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mini Varghese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.